This project aims to find new biomarkers for immunotherapy in patients with melanoma.
About this clinical trial
Cancer immunotherapy has been shown to provide patients with an excellent new type of treatment and is in common use world-wide. Unfortunately, we know that not all patients will respond to their immunotherapy treatment in the same way.
Responses to immunotherapy may be affected by a patient’s microbiome, or the community of bacteria that live in their bowel. This group of bacteria can influence the immune system by increasing or decreasing certain types of white cells, called T cells that are produced in the body. By analysing the bacteria, this project aims to find new biomarkers for immunotherapy in patients with melanoma.
Finding new biomarkers for immunotherapy in patients with melanoma
Metabolomics in Enhancing Responses to Cancer ImmunoTherapy in Melanoma (MERIT-M)
Register your interest
If you would like more information about this clinical trial, please complete the contact form below.